Reported Earlier, BridgeBio's Acoramidis Shows 42% Reduction in Mortality and Heart Hospitalizations in ATTR-CM Study, New Drug Application Under FDA Review
Portfolio Pulse from Benzinga Newsdesk
BridgeBio Pharma's drug acoramidis shows a 42% reduction in mortality and heart hospitalizations in a Phase 3 study for ATTR-CM. The company has submitted a New Drug Application to the FDA, with a decision expected by November 2024.
September 30, 2024 | 7:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BridgeBio Pharma's acoramidis demonstrated a 42% reduction in mortality and heart hospitalizations in a Phase 3 study for ATTR-CM. The FDA is reviewing their New Drug Application, with a decision expected by November 2024.
The significant reduction in mortality and hospitalizations in the Phase 3 study is a positive indicator for acoramidis' potential approval. The FDA's acceptance of the New Drug Application and the upcoming decision date add to the positive outlook for BridgeBio.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100